Compare OTLK & XFLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OTLK | XFLT |
|---|---|---|
| Founded | 2010 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 249.6M | 250.4M |
| IPO Year | 2016 | 2017 |
| Metric | OTLK | XFLT |
|---|---|---|
| Price | $0.38 | $15.23 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $4.82 | N/A |
| AVG Volume (30 Days) | ★ 3.2M | 107.1K |
| Earning Date | 12-18-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 14.17% |
| EPS Growth | ★ 55.91 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $8,146,123.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6,315.49 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.16 | $3.02 |
| 52 Week High | $2.54 | $19.63 |
| Indicator | OTLK | XFLT |
|---|---|---|
| Relative Strength Index (RSI) | 34.43 | 24.45 |
| Support Level | $0.19 | $3.05 |
| Resistance Level | $0.39 | $19.53 |
| Average True Range (ATR) | 0.04 | 0.35 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 18.07 | 1.32 |
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
XAI Octagon Floating Rate & Alternative Income Trust is a diversified, closed-end management investment company which invests in a dynamically managed portfolio of floating-rate credit instruments and other structured credit investments within the private markets. The Trust's investment objective is to seek attractive total return with an emphasis on income generation across multiple stages of the credit cycle.